What is the optimal diabetes management strategy for a patient with heart failure with reduced ejection fraction (HFrEF)?

Optimal Diabetes Management in HFrEF: SGLT2 Inhibitors as First-Line Therapy

In patients with HFrEF and diabetes, SGLT2 inhibitors (dapagliflozin 10 mg daily or empagliflozin 10 mg daily) should be initiated immediately as foundational therapy to reduce cardiovascular mortality, heart failure hospitalization, and improve quality of life—regardless of current glycemic control or other antidiabetic medications. This recommendation is based on strong guideline evidence demonstrating that SGLT2 inhibitors provide cardiovascular and mortality benefits that extend far beyond glucose lowering 1.

Why SGLT2 Inhibitors Are Non-Negotiable in HFrEF with Diabetes

The 2021 CCS/CHFS guidelines provide the strongest evidence base: SGLT2 inhibitors reduce the composite of cardiovascular death or heart failure hospitalization by approximately 25-30% in patients with HFrEF, with consistent benefits whether diabetes is present or not 1. The landmark DAPA-HF and EMPEROR-Reduced trials demonstrated these benefits were added on top of maximally tolerated guideline-directed medical therapy (ACE inhibitors/ARBs/ARNI, beta-blockers, mineralocorticoid receptor antagonists) 1.

Critically, the cardiovascular benefits of SGLT2 inhibitors are disproportionate to their glucose-lowering effects, suggesting mechanisms beyond glycemic control—including improved myocardial energetics, reduced preload/afterload through osmotic diuresis, anti-inflammatory effects, and direct cardioprotective actions 2, 3.

Practical Implementation Algorithm

Step 1: Initiate SGLT2 Inhibitor Early

• Start dapagliflozin 10 mg daily OR empagliflozin 10 mg daily 1, 4
• Do NOT wait for optimization of other heart failure medications
• Can be started as early as the disease course as eligible 1
• The 2021 guidelines explicitly state it is reasonable to start this therapy early, recognizing the significant residual risk despite other guideline-directed medical therapy 1

Step 2: Check Renal Function Before Initiation

• eGFR ≥30 mL/min/1.73 m² is required for dapagliflozin (DAPA-HF exclusion criterion) 1
• eGFR ≥20 mL/min/1.73 m² is required for empagliflozin (EMPEROR-Reduced exclusion criterion) 1
• Once started, SGLT2 inhibitors may be continued even if eGFR falls below 30 mL/min/1.73 m², as long as they are well-tolerated and kidney replacement therapy is not imminent 2
• Expect a modest, reversible hemodynamic reduction in eGFR (up to 15%) within the first 1-3 months—this is NOT a reason to discontinue 1

Step 3: Address Additional Glucose-Lowering Needs

After establishing SGLT2 inhibitor therapy, assess if additional glycemic control is needed:

If HbA1c remains elevated despite SGLT2 inhibitor:

• Add metformin if eGFR ≥45 mL/min/1.73 m² (reduce dose if eGFR 30-44 mL/min/1.73 m²; discontinue if <30 mL/min/1.73 m²) 2
• Consider GLP-1 receptor agonists (long-acting formulations like semaglutide or liraglutide) for additional cardiovascular benefit and weight reduction 2
• Avoid or minimize sulfonylureas and insulin when possible due to hypoglycemia risk; if already on these agents, consider dose reduction when adding SGLT2 inhibitor 2

If HbA1c is at goal but patient is on insulin or sulfonylureas:

• Reduce doses of insulin or sulfonylureas to prevent hypoglycemia when adding SGLT2 inhibitor 2

Critical Safety Considerations and Monitoring

Common Pitfalls to Avoid

1. Genital Mycotic Infections (10-15% in women, lower in men)

   • Highest risk: women, uncircumcised men, prior history of infections 1
   • Management: topical antifungals; rarely requires discontinuation 1

2. Volume Depletion

   • SGLT2 inhibitors cause modest osmotic diuresis
   • Action: Consider reducing loop diuretic dose in patients at risk for hypovolemia 2
   • Educate patients on symptoms of volume depletion and low blood pressure 2

3. Diabetic Ketoacidosis (DKA)

   • Absolute contraindication in type 1 diabetes 1
   • Rare in type 2 diabetes but can occur during acute illness, surgery, or severe carbohydrate restriction
   • Sick day management: Hold SGLT2 inhibitor during acute illness, dehydration, or prolonged fasting 1

4. Acute Kidney Injury

   • Monitor eGFR within first few weeks, then periodically 1
   • Temporary eGFR reduction (up to 15%) is expected and reversible—do not discontinue unless acute kidney injury is suspected 1

Monitoring Schedule

• Baseline: eGFR, electrolytes, HbA1c, blood pressure, weight
• 2-4 weeks: eGFR, electrolytes (watch for hyperkalemia if on MRA), blood pressure
• 3 months: eGFR, HbA1c, assess volume status and adverse effects
• Ongoing: eGFR and HbA1c every 3-6 months; assess for genital infections at each visit

Additional Cardiovascular Benefits Beyond HFrEF

The 2021 CCS/CHFS guidelines also recommend SGLT2 inhibitors for:

• Patients with diabetes and atherosclerotic cardiovascular disease (empagliflozin, canagliflozin, or dapagliflozin) to reduce heart failure hospitalization and death 1
• Patients with diabetes and albuminuric chronic kidney disease (canagliflozin or dapagliflozin) to reduce heart failure hospitalization and slow CKD progression 1
• The DAPA-CKD trial showed dapagliflozin reduced all-cause mortality by 31% (HR 0.69) in patients with CKD and albuminuria, with or without diabetes 1

What About Other Antidiabetic Agents?

Metformin: Safe and effective first-line agent for glucose control, but lacks the cardiovascular mortality benefit of SGLT2 inhibitors in HFrEF. Use as adjunctive therapy if additional glucose lowering is needed 2.

GLP-1 Receptor Agonists: Long-acting GLP-1 RAs (semaglutide, liraglutide, dulaglutide) reduce major adverse cardiovascular events in patients with diabetes and established cardiovascular disease, but their specific benefit in HFrEF is less robust than SGLT2 inhibitors 2. Consider as second-line for additional glucose control and weight loss.

DPP-4 Inhibitors: Saxagliptin has been associated with increased heart failure hospitalization and should be avoided in HFrEF 2. Other DPP-4 inhibitors are neutral but offer no cardiovascular benefit.

Thiazolidinediones: Cause fluid retention and are contraindicated in heart failure 2.

Insulin and Sulfonylureas: Increase hypoglycemia risk without cardiovascular benefit. Minimize use when possible 2.

The Bottom Line

SGLT2 inhibitors are not just antidiabetic agents—they are foundational heart failure therapy that happen to lower glucose. In patients with HFrEF and diabetes, they should be initiated immediately alongside other guideline-directed medical therapy (ACE inhibitors/ARBs/ARNI, beta-blockers, MRAs) to reduce mortality and hospitalization 1, 4. The 2025 ADA guidelines reinforce this, stating that SGLT2 inhibitors with proven heart failure benefit are recommended in patients with type 2 diabetes and established heart failure to reduce worsening heart failure and cardiovascular death 5.

Start with dapagliflozin 10 mg daily or empagliflozin 10 mg daily, monitor renal function and volume status, educate on sick day management, and add other glucose-lowering agents only if needed for glycemic control 1, 2, 4.